From Being Patient: With research for the recently FDA-approved Leqembi still in clinical trials and other Alzheimer’s research ongoing, many are considering whether to be a part of the research. While some participants, like Live Talks guest Gordon Van Slyke, have positive experiences with clinical trials, some participants don’t feel fully supported or heard by centers running trials. With many trials ending early, some researchers are investigating how trials can treat participants better and support them through the process. Dr. Emily Largent is the Emanuel and Robert Hart Assistant Professor of Medical Ethics and Health Policy at Perelman School of Medicine at the University of Pennsylvania. In her recent study, she examined some of the critical reasons Alzheimer’s clinical trials can end early and some fundamental approaches to improving the trial experience for participants. Her work focuses on neurodegenerative diseases like Alzheimer’s, and she focuses on the social, legal, and ethical aspects scientists should consider when research findings are applied to care. She joined Being Patient Live Talks to discuss this research and how more trials could put participants with Alzheimer’s first. Listen to the full conversation at Being Patient.